Pharmacologic therapy for inflammatory bowel disease refractory to steroids
about
Explore Small Molecule-induced Genome-wide Transcriptional Profiles for Novel Inflammatory Bowel Disease DrugPalmitoylethanolamide Modulates Inflammation-Associated Vascular Endothelial Growth Factor (VEGF) Signaling via the Akt/mTOR Pathway in a Selective Peroxisome Proliferator-Activated Receptor Alpha (PPAR-α)-Dependent Manner.Review article: the many potential roles of intestinal serotonin (5-hydroxytryptamine, 5-HT) signalling in inflammatory bowel disease.
P2860
Pharmacologic therapy for inflammatory bowel disease refractory to steroids
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Pharmacologic therapy for inflammatory bowel disease refractory to steroids
@ast
Pharmacologic therapy for inflammatory bowel disease refractory to steroids
@en
Pharmacologic therapy for inflammatory bowel disease refractory to steroids
@nl
type
label
Pharmacologic therapy for inflammatory bowel disease refractory to steroids
@ast
Pharmacologic therapy for inflammatory bowel disease refractory to steroids
@en
Pharmacologic therapy for inflammatory bowel disease refractory to steroids
@nl
prefLabel
Pharmacologic therapy for inflammatory bowel disease refractory to steroids
@ast
Pharmacologic therapy for inflammatory bowel disease refractory to steroids
@en
Pharmacologic therapy for inflammatory bowel disease refractory to steroids
@nl
P2093
P2860
P3181
P356
P1476
Pharmacologic therapy for inflammatory bowel disease refractory to steroids
@en
P2093
A Masedo-González
B Casis-Herce
C Piedracoba
C Yela-San Bernardino
G Castellano-Tortajada
G J Gómez-Gómez
P2860
P304
P3181
P356
10.2147/CEG.S58152
P407
P577
2015-08-17T00:00:00Z